Recent advances in biomedical engineering are opening new frontiers for temporary pacemaker devices, with biodegradable power sources emerging as a transformative innovation. These power sources, designed to safely dissolve in the body after their job is done, promise to eliminate the need for surgical extraction, reduce medical waste, and lower the risk of complications. Traditional temporary pacemakers rely on non-degradable batteries that must be removed once therapy ends, a procedure that exposes patients to infection, tissue damage, and additional healthcare costs. By contrast, biodegradable batteries offer a safer, more sustainable alternative that could reshape cardiac care for millions of patients worldwide.

The Case for Biodegradable Power Sources

Clinical and Economic Benefits of Device Removal Avoidance

In the United States alone, over 90,000 permanent pacemakers are implanted annually, and a significant fraction of those are temporary devices used during recovery from cardiac surgery, as a bridge to permanent implantation, or for reversible conditions such as infections or drug-induced arrhythmias. Current temporary pacemakers are powered by miniature lithium-ion or silver-oxide batteries that are not designed to degrade. When the device is no longer needed, an invasive retrieval procedure is required—often a second operation under anesthesia. This adds risk of infection (reported rates of 1–3% for lead extraction), hemorrhage, and even cardiac tamponade. The economic burden is also substantial: extraction procedures can cost $10,000–$20,000 per case, not counting patient recovery time. Biodegradable power sources eliminate these costs and risks by allowing the entire device to be absorbed or excreted harmlessly after a predetermined period.

Environmental and Sustainability Considerations

The medical device industry produces millions of used batteries every year, many of which contain toxic metals, lithium cobalt oxide, or organic electrolytes that require special disposal. A biodegradable battery that breaks down into benign byproducts—such as magnesium hydroxide, silicon dioxide, or lactic acid—dramatically reduces the environmental footprint of temporary implants. This aligns with the growing demand for eco‑friendly healthcare solutions and regulatory pressures, such as the European Union’s Medical Device Regulation (MDR) requirements for sustainability. Hospitals and manufacturers are increasingly seeking materials that can be composted or safely eliminated without entering the waste stream.

Current Temporary Pacemaker Battery Technologies: Limitations

Today’s temporary pacemaker systems rely on primary (non-rechargeable) lithium batteries or, in older designs, zinc–air cells. While these chemistries provide reliable power for weeks to months, they are not bioresorbable. Even the packaging—typically titanium, stainless steel, or polymer enclosures—must be surgically removed. No standard temporary pacemaker today offers a fully degradable energy source. Research into biodegradable alternatives has accelerated in the past decade, but clinical translation has been slow due to challenges in balancing power density, degradation rate, and safety.

Types of Emerging Biodegradable Batteries

Silicon‑Based Batteries

Silicon is attractive for biodegradable electronics because it can be engineered to dissolve slowly in physiological fluids. Researchers at the University of Illinois and elsewhere have developed thin‑film silicon anodes and cathodes that degrade into orthosilicic acid, a non‑toxic compound excreted by the kidneys. Silicon‑based batteries have demonstrated energy densities of 10–50 mWh/cm³, sufficient to power a temporary pacemaker for several days to weeks. However, the degradation rate must be tightly controlled—too fast and the battery fails prematurely; too slow and it remains long after needed. Recent work focuses on doping silicon with other elements or applying biocompatible coatings to fine‑tune the dissolution timeline.

Magnesium‑Based Batteries

Magnesium is a compelling anode material because it corrodes electrochemically in aqueous environments, producing magnesium hydroxide and hydrogen gas. Laboratory prototypes have achieved open‑circuit voltages of 1.2–1.6 V and current densities suitable for pacemaker microcontrollers and pacing pulses. A landmark study from the National University of Singapore demonstrated a magnesium‑air battery that powered a commercial pacemaker chip for 10 days before complete degradation in simulated body fluid. Challenges include managing hydrogen evolution (which can cause gas pockets) and ensuring that the byproducts do not provoke an inflammatory response. New magnesium alloys with controlled corrosion rates and reduced hydrogen output are under investigation.

Organic Batteries

Organic electrodes—such as conjugated polymers, quinones, and melanin—offer inherent biocompatibility and tunable degradation. Researchers at MIT have created a battery using poly(3,4‑ethylenedioxythiophene) (PEDOT) as the cathode and a biodegradable hydrogel electrolyte. These devices break down into harmless small molecules that can be metabolized. Energy densities remain lower than inorganic counterparts (around 5–20 mWh/cm³), but they excel in flexibility and softness, matching the mechanical properties of cardiac tissue. Organic batteries are particularly promising for fully transient sensor–actuator systems where mechanical compliance reduces tissue damage.

Other Emerging Chemistries

Zinc‑based biodegradable batteries leverage zinc’s electrochemical activity and corrosion byproducts that are essential micronutrients (Zn²⁺). Similarly, iron‑based systems degrade into iron oxides and are resorbed. Both chemistries show moderate energy densities and can be fabricated in thin‑film or printed formats. Recent work at the University of Texas combined zinc with a starch‑based separator to create a fully biodegradable cell that powered a LED for two weeks. For temporary pacemakers, these materials are still in early lab validation but offer a path toward low‑cost, scalable production.

Advantages Beyond Waste Reduction

  • Patient Safety: Avoiding extraction procedures eliminates a major source of infection, bleeding, and cardiac injury. The risk of pacemaker lead fracture and retention is also removed.
  • Cost Savings: One extraction procedure can cost $15,000 or more. Eliminating this step reduces total treatment cost by an estimated 20–30% for temporary pacing.
  • Reduced Surgical Burden: Patients who require temporary pacing due to acute conditions (e.g., post‑surgery, myocarditis) may only need a single implantation surgery. Hospital stays and anesthesia exposures are shortened.
  • Environmental Stewardship: Biodegradable batteries can be designed to degrade into non‑toxic compounds, reducing the accumulation of heavy metals and plastics in medical waste streams.
  • Design Freedom: Degradable materials can be combined with wireless power harvesting or biodegradable sensors, enabling completely transient pacemaker systems that disappear when no longer needed.

Scientific and Engineering Challenges

Power Output and Longevity

Temporary pacemakers typically require 5–50 µW of continuous power and incremental pulses of several milliwatts for pacing. Current biodegradable chemistries achieve energy densities of 10–100 mWh/cm³, which translates to several days to a few weeks of operation in millimeter‑scale cells. Extending runtime to the typical 1–3 months required for temporary bridging remains a major hurdle. Strategies include stacking multiple cells, using higher‑voltage materials, or integrating energy harvesting (e.g., piezoelectric or triboelectric) to supplement the battery.

Controlling Degradation Rate

The battery must maintain stable voltage and current until the intended end of life, then degrade predictably within a few days. Variability in patient physiology (pH, ion concentration, temperature) can accelerate or delay dissolution. Encapsulation layers, such as poly(lactic‑co‑glycolic acid) (PLGA) or silicon dioxide, are used to slow degradation initially and then allow rapid breakdown after a programmed trigger (e.g., absorption of the barrier). Achieving precise temporal control without active electronics is an active research area.

Biocompatibility and Toxicity

All degradation byproducts must be non‑toxic and cleared by the body without causing inflammation or interfering with healing. Magnesium and zinc byproducts are generally well tolerated, but high local concentrations can cause tissue irritation or fibrosis. In vivo studies in animal models (pigs, rabbits) have shown acceptable safety profiles for short‑term implants, but long‑term data are still missing. The US Food and Drug Administration (FDA) requires rigorous biocompatibility testing per ISO 10993—including cytotoxicity, sensitization, and systemic toxicity—before clinical trials can proceed.

Packaging and Sterilization

Biodegradable materials must survive standard sterilization processes (e.g., ethylene oxide, electron beam) without degrading prematurely. Moreover, the packaging must be hermetic enough to prevent moisture ingress during storage but allow controlled degradation once implanted. Researchers are exploring anhydrous packaging that dissolves only after contact with bodily fluids.

Recent Research and Notable Studies

A 2021 study published in Nature Biomedical Engineering described a magnesium‑molybdenum dioxide battery that powered a pacemaker lead for 21 days in a canine model. The battery degraded completely within 8 weeks, with no adverse effects on cardiac function or blood chemistry. That same year, a team from Stanford University demonstrated a silicon‑based battery integrated with a biodegradable wireless receiver, enabling reprogramming and real‑time data transmission—a step toward fully transient smart pacemakers. In 2023, Swiss researchers reported an organic lithium‑ion battery using polypyrrole electrodes and a cellulose separator; it provided stable pacing for 10 days in rabbit hearts and dissolved within 30 days, with all byproducts cleared via the kidneys.

Clinical translation is accelerating: at least two start‑ups have received FDA breakthrough device designation for biodegradable temporary pacing systems, with human feasibility studies expected to begin in 2025. Ongoing research aims to triple energy density while maintaining safe dissolution profiles.

Integration with Future Cardiac Devices

Biodegradable batteries are often combined with near‑field communication (NFC) or radiofrequency harvesting coils that can be used for charging or real‑time data transmission. Because the coils themselves are made from degradable metals (e.g., magnesium), the entire system disappears after use. This approach could eliminate the need for transcutaneous leads, further reducing infection risk. A fully biodegradable pacemaker already prototyped by researchers at the University of Connecticut includes a multifunctional chip that regulates pacing, monitors cardiac rhythm, and transmits data to an external reader—all powered by a zinc‑air battery that lasts 30 days.

Sensor Integration

Future temporary pacemakers could incorporate biodegradable sensors for pH, temperature, or local pressure to guide therapy. For instance, if inflammation is detected, the device could adjust pacing parameters or trigger a drug‑eluting layer. These sensors could also be used to trigger the pacemaker’s own degradation when the heart’s natural rhythm returns, creating a closed‑loop system that eliminates the need for clinician intervention.

Regulatory and Clinical Translation Hurdles

The path to market for biodegradable power sources involves unique regulatory challenges. The FDA and European Medicines Agency (EMA) currently classify such devices as combination products (device + drug), since the degradation products may be considered biologically active. This requires additional toxicology and pharmacokinetic studies to demonstrate that the byproducts do not accumulate or cause delayed effects. Furthermore, manufacturers must prove that the device’s degradation timeline can be reliably predicted and that it does not leave behind any non‑degradable fragments. Pre‑clinical animal studies simulating the full implant duration are essential. Despite these hurdles, the FDA has issued guidance for biodegradable medical devices, and several pre‑submission meetings have taken place, indicating growing regulatory acceptance.

Future Outlook and Conclusion

Biodegradable power sources represent one of the most exciting developments in temporary pacemaker technology. By removing the need for surgical extraction, these power sources improve patient outcomes, lower healthcare costs, and reduce environmental impact. While challenges remain—particularly in energy density, degradation control, and regulatory validation—the pace of innovation is accelerating. In the next five years, we can expect to see the first‑in‑human trials of fully biodegradable temporary pacemakers, followed by limited clinical use for high‑risk or short‑term indications. As materials science and wireless technology continue to advance, the vision of a completely transient, eco‑friendly cardiac support system is becoming a tangible reality.

The integration of biodegradable batteries with advanced sensors and wireless power will not only transform cardiac care but also set a precedent for sustainable medical devices across many other fields—from wound healing to neural stimulation. The era of the “disappearing” pacemaker is on the horizon, promising a safer, cleaner, and more patient‑centered approach to life‑saving therapy.